Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Renal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00678119
What this trial is testing

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Who this might be right for
Renal Cell Carcinoma
Argos Therapeutics 25
Not applicableLooking for participantsNCT07327489
What this trial is testing

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Who this might be right for
CancerImmunotherapyAdvanced Solid Tumors Cancer+12 more
Elephas 2,000
Testing effectiveness (Phase 2)Study completedNCT03200717
What this trial is testing

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

Who this might be right for
Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Novartis Pharmaceuticals 62
Early research (Phase 1)Not Yet RecruitingNCT07252661
What this trial is testing

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

Who this might be right for
Hepatocellular CarcinomaRenal Cell CarcinomaThyroid Carcinoma, Medullary+6 more
AccSalus Biosciences, Inc. 40
Early research (Phase 1)Ended earlyNCT01240642
What this trial is testing

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Who this might be right for
Metastatic Cancer With Impaired Renal FunctionMetastatic Cancer With Normal Renal Function
Novartis Pharmaceuticals 27
Early research (Phase 1)Study completedNCT01772004
What this trial is testing

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 1,756
Testing effectiveness (Phase 2)Study completedNCT03233204
What this trial is testing

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+33 more
National Cancer Institute (NCI) 6
Early research (Phase 1)Study completedNCT01588678
What this trial is testing

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Advanced Solid TumorLymphoma
Daiichi Sankyo 32
Not applicableActive Not RecruitingNCT03647878
What this trial is testing

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

Who this might be right for
Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Ipsen 224
Testing effectiveness (Phase 2)Study completedNCT01282463
What this trial is testing

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Who this might be right for
Carcinoma of Urinary TractUrethral CarcinomaCarcinoma of Ureter+1 more
Eli Lilly and Company 148
Not applicableStudy completedNCT04353765
What this trial is testing

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Who this might be right for
Locally Advanced or Metastatic Renal Cell Carcinoma
Ipsen 247
Early research (Phase 1)Active Not RecruitingNCT04606472
What this trial is testing

SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT05155033
What this trial is testing

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Who this might be right for
Metastatic MelanomaAdvanced Locoregional MelanomaMetastatic Renal Cell Carcinoma+1 more
National Cancer Institute (NCI) 78
Early research (Phase 1)Study completedNCT00066404
What this trial is testing

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Who this might be right for
Cancer
Abramson Cancer Center at Penn Medicine
Testing effectiveness (Phase 2)Active Not RecruitingNCT00365157
What this trial is testing

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Who this might be right for
Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+4 more
National Cancer Institute (NCI) 171
Testing effectiveness (Phase 2)Ended earlyNCT01727336
What this trial is testing

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Advanced Renal Cell Carcinoma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 160
Testing effectiveness (Phase 2)Looking for participantsNCT06682793
What this trial is testing

Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more
A2 Biotherapeutics Inc. 240
Large-scale testing (Phase 3)Study completedNCT00942331
What this trial is testing

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Who this might be right for
Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Prostate Carcinoma+10 more
National Cancer Institute (NCI) 506
Testing effectiveness (Phase 2)Looking for participantsNCT05944237
What this trial is testing

HTL0039732 in Participants With Advanced Solid Tumours

Who this might be right for
NeoplasmsProstatic Neoplasms, Castration-ResistantStomach Neoplasms+11 more
Cancer Research UK 150
Not applicableStudy completedNCT00836745
What this trial is testing

Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent

Who this might be right for
Renal Cell Carcinoma
Pfizer 36
Next Page